PT  - JOURNAL ARTICLE
AU  - Sierra, Leandro
AU  - Liu, Lily
AU  - Khurana, Akash
AU  - Patel, Roma
AU  - Chatterjee, Arjun
AU  - Firkins, Stephen
AU  - Simons-Linares, Roberto
TI  - Reversing fibrosis in metabolic dysfunction–associated steatohepatitis—beyond telling patients to lose weight
AID  - 10.3949/ccjm.93a.25082
DP  - 2026 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 279--286
VI  - 93
IP  - 5
4099  - http://www.ccjm.org/content/93/5/279.short
4100  - http://www.ccjm.org/content/93/5/279.full
SO  - Cleve Clin J Med2026 May 01; 93
AB  - To reverse fibrosis in late-stage metabolic dysfunction–associated steatohepatitis (MASH), guidelines recommend that patients shed at least 10% of their body weight. However, losing this much weight remains a challenge for most patients, especially with lifestyle modifications alone. Moreover, not all patients with MASH are overweight or obese. This review summarizes pharmacologic, surgical, and bariatric endoscopic treatments for MASH to guide primary care physicians and internists.